1-(2,6-diisopropylphenyl)-3-((1-(4-fluorophenyl)cyclopentyl)methyl)urea

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2,6-diisopropylphenyl)-3-((1-(4-fluorophenyl)cyclopentyl)methyl)urea
• 英文别名: N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-(4-fluorophenyl)cyclopentyl]methyl]urea；1-(2,6-Diisopropyl-phenyl)-3-[1-(4-fluoro-phenyl)-cyclopentylmethyl]-urea；1-[2,6-di(propan-2-yl)phenyl]-3-[[1-(4-fluorophenyl)cyclopentyl]methyl]urea
• 化学式: C₂₅H₃₃FN₂O
• 分子量: 396.548
• InChiKey: FMZVCBFPBHDUQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  C-[1-(4-氟-苯基)-环戊基]-甲胺 、 2,6-二异丙基苯异氰酸酯 以 乙酸乙酯 为溶剂， 反应 0.17h， 以89%的产率得到1-(2,6-diisopropylphenyl)-3-((1-(4-fluorophenyl)cyclopentyl)methyl)urea
  参考文献：
  名称：

  Synthesis and Evaluation of ¹¹C- and ¹⁸F-Labeled SOAT1 Inhibitors as Macrophage Foam Cell Imaging Agents

  摘要：

  PD-132301, an inhibitor of sterol O-acyltransferase 1 (SOAT1; also known as acyl-coenzyme A:cholesterol acyltransferase-1, ACAT1), is under clinical investigation for numerous adrenal disorders. Radiolabeled SOAT1 inhibitors could support drug discovery and help diagnose SOAT1-related disorders, such as atherosclerosis. We synthesized two radiolabeled SOAT1 inhibitors, [C-11]PD-132301 and fluorine analogue [F-18]1. Rat biodistribution studies were conducted with both agents and, as the most selective tracer, [C-11]PD-132301 was advanced to preclinical positron emission tomography studies in (atherosclerotic) ApoE(-/-) mice. The uptake of [C-11]PD-132301 in SOAT1-rich tissue warrants further investigation into the compound as an atherosclerosis and adrenal imaging agent.

  DOI：

  10.1021/acsmedchemlett.0c00127

文献信息

• US5015644A
  申请人：——

  公开号：US5015644A

  公开（公告）日：1991-05-14
• Synthesis and Evaluation of ¹¹C- and ¹⁸F-Labeled SOAT1 Inhibitors as Macrophage Foam Cell Imaging Agents
  作者：James R. Hill、Xia Shao、Jay S. Wright、Jenelle Stauff、Phillip S. Sherman、Janna Arteaga、Ka Kit Wong、Benjamin L. Viglianti、Peter J. H. Scott、Allen F. Brooks

  DOI：10.1021/acsmedchemlett.0c00127

  日期：2020.6.11

  PD-132301, an inhibitor of sterol O-acyltransferase 1 (SOAT1; also known as acyl-coenzyme A:cholesterol acyltransferase-1, ACAT1), is under clinical investigation for numerous adrenal disorders. Radiolabeled SOAT1 inhibitors could support drug discovery and help diagnose SOAT1-related disorders, such as atherosclerosis. We synthesized two radiolabeled SOAT1 inhibitors, [C-11]PD-132301 and fluorine analogue [F-18]1. Rat biodistribution studies were conducted with both agents and, as the most selective tracer, [C-11]PD-132301 was advanced to preclinical positron emission tomography studies in (atherosclerotic) ApoE(-/-) mice. The uptake of [C-11]PD-132301 in SOAT1-rich tissue warrants further investigation into the compound as an atherosclerosis and adrenal imaging agent.